{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:56:26Z","timestamp":1722621386920},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.medcli.2018.10.010","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T16:14:20Z","timestamp":1543335260000},"page":"310-316","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Marcadores de actividad en la enfermedad inflamatoria intestinal"],"prefix":"10.1016","volume":"152","author":[{"given":"Juan","family":"Egea Valenzuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Ant\u00f3n R\u00f3denas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"S\u00e1nchez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2018.10.010_bib0305","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.trsl.2012.01.001","article-title":"Biomarkers in inflammatory bowel disease: Current practices and recent advances","volume":"159","author":"Iskandar","year":"2012","journal-title":"Transl Res"},{"key":"10.1016\/j.medcli.2018.10.010_bib0310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.medcli.2013.09.047","article-title":"Concordancia entre la actividad cl\u00ednica y los marcadores biol\u00f3gicos en la enfermedad inflamatoria intestinal","volume":"144","author":"Miranda Garc\u00eda","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2018.10.010_bib0315","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of inflammation in inflammatory bowel disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2018.10.010_bib0320","first-page":"90","article-title":"Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis","volume":"44","author":"Niederau","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.medcli.2018.10.010_bib0325","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/00365520500217118","article-title":"Clinically active Crohn's disease in the presence of a low C-reactive protein","volume":"41","author":"Florin","year":"2006","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.medcli.2018.10.010_bib0330","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00054725-200409000-00026","article-title":"C-reactive protein as a marker for inflammatory bowel disease","volume":"10","author":"Vermeire","year":"2004","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.medcli.2018.10.010_bib0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00005176-200405000-00009","article-title":"Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine","volume":"38","author":"Barnes","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10.1016\/j.medcli.2018.10.010_bib0340","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-2036.2010.04459.x","article-title":"Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn's disease","volume":"32","author":"Oussalah","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2018.10.010_bib0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijsu.2016.10.011","article-title":"Procalcitonin in Crohn's disease with fever episodes, a variable to differentiate intra-abdominal abscess from disease flares","volume":"36","author":"Ge","year":"2016","journal-title":"Int J Surg"},{"key":"10.1016\/j.medcli.2018.10.010_bib0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clinbiochem.2017.12.007","article-title":"Elevation of serum pyruvate kinase M2 (PKM2) in IBD and its relationship to IBD indices","volume":"53","author":"Almousa","year":"2018","journal-title":"Clin Biochem"},{"key":"10.1016\/j.medcli.2018.10.010_bib0355","first-page":"155","article-title":"Biomarkers in inflammatory bowel diseases: Insight into diagnosis, prognosis and treatment","volume":"10","author":"Norouzinia","year":"2017","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"10.1016\/j.medcli.2018.10.010_bib0360","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/ajg.2010.95","article-title":"Disease activity, ANCA, and IL23R geno-type status determine early response to infliximab in patients with ulcerative colitis","volume":"105","author":"J\u00fcrgens","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0365","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/apt.12274","article-title":"Meta-analysis: Serological markers and the risk of acute and chronic pouchitis","volume":"37","author":"Singh","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2018.10.010_bib0370","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ecco-jcc\/jjw021","article-title":"Concordance in anti-OmpC and anti-I2 indicate the influence of genetic predisposition: results of a European Study of Twins with Crohn's Disease","volume":"10","author":"Amcoff","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0375","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug anti-bodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2018.10.010_bib0380","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jgh.13611","article-title":"Fecal biomarkers in inflammatory bowel disease","volume":"32","author":"Lopez","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0385","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00042737-200208000-00005","article-title":"Fecal calprotectin: A marker of inflammation throughout the intestinal tract","volume":"14","author":"Summerton","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0390","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0167-4889(99)00058-0","article-title":"Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type","volume":"1450","author":"Donato","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.medcli.2018.10.010_bib0395","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.4049\/jimmunol.170.6.3233","article-title":"Proinflammatory activities of S100: Proteins S100A8 S100A9, and S100A8\/A9 induce neutrophil chemotaxis and adhesion","volume":"170","author":"Ryckman","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0400","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2008.05.008","article-title":"Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease","volume":"41","author":"Gisbert","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0405","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/gut.34.10.1357","article-title":"Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes","volume":"34","author":"Bjerke","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2018.10.010_bib0410","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4321\/S1130-01082007001200001","article-title":"Calprotectina fecal","volume":"99","author":"Rodrigo","year":"2007","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.medcli.2018.10.010_bib0415","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1440-1746.2003.03014.x","article-title":"Emerging role of calprotectin in gastroenterology","volume":"18","author":"Poullis","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0420","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/00365521.2015.1066421","article-title":"Effect of oral diclofenac intake on faecal calprotectin","volume":"51","author":"Rendek","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0425","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2007.01126.x","article-title":"Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy","volume":"102","author":"Von Roon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0430","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00384-014-1884-0","article-title":"Increased faecal calprotectin predicts recurrence of colonic diverticulitis","volume":"29","author":"Tursi","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0435","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/MCG.0b013e3181cadbc0","article-title":"Fecal calprotectin concentration in celiac disease","volume":"44","author":"Ertekin","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0440","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000116777","article-title":"Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth","volume":"26","author":"Montalto","year":"2008","journal-title":"Dig Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0445","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3343\/alm.2017.37.1.53","article-title":"Fecal calprotectin level reflects the severity of Clostridium difficile infection","volume":"37","author":"Kim","year":"2017","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.medcli.2018.10.010_bib0450","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1157\/13090002","article-title":"Precisi\u00f3n diagn\u00f3stica de la calprotectina fecal para predecir una colonoscopia patol\u00f3gica","volume":"127","author":"Garc\u00eda S\u00e1nchez","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2018.10.010_bib0455","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0460","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.gastrohep.2016.04.009","article-title":"Calprotectina fecal, marcador eficaz en la diferenciaci\u00f3n de enfermedades inflamatorias intestinales y trastornos funcionales gastrointestinales","volume":"40","author":"Lozoya Angulo","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0465","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c3369","article-title":"Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis","volume":"341","author":"Van Rheenen","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2018.10.010_bib0470","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cgh.2013.06.028","article-title":"Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children","volume":"12","author":"Yang","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0475","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/flgastro-2016-100762","article-title":"Practical guidance on the use of faecal calprotectin","volume":"9","author":"Brookes","year":"2018","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0480","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4292\/wjgpt.v8.i1.39","article-title":"Update on clinical and research application of fecal biomarkers for gastrointestinal diseases","volume":"8","author":"Siddiqui","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.medcli.2018.10.010_bib0485","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/flgastro-2014-100467","article-title":"Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations?","volume":"6","author":"Seenan","year":"2015","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0490","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1055\/s-0034-1391855","article-title":"Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline","volume":"47","author":"Pennazio","year":"2015","journal-title":"Endoscopy"},{"key":"10.1016\/j.medcli.2018.10.010_bib0495","first-page":"211","article-title":"Calprotectina fecal como predictor de lesiones inflamatorias en intestino delgado diagnosticadas con c\u00e1psula endosc\u00f3pica","volume":"107","author":"Egea Valenzuela","year":"2015","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.medcli.2018.10.010_bib0500","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/00365521.2016.1253769","article-title":"A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy","volume":"52","author":"Bar-Gil Shitrit","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0505","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/MEG.0000000000000692","article-title":"Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: A systematic review and meta-analysis","volume":"28","author":"Kopylov","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0510","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MEG.0000000000001083","article-title":"Development and validation of a scoring index to predict the presence of lesions in capsule endoscopy in patients with suspected Crohn's disease of the small bowel: A Spanish multicenter study","volume":"30","author":"Egea Valenzuela","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0515","first-page":"394","article-title":"Calprotectina y prote\u00edna C reactiva se asocian a hallazgos en c\u00e1psula endosc\u00f3pica de pacientes con sospecha de enfermedad de Crohn de intestino delgado","volume":"108","author":"Egea Valenzuela","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.medcli.2018.10.010_bib0520","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/00365521.2014.920915","article-title":"Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease","volume":"49","author":"H\u00f6\u00f6g","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0525","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12876-017-0669-7","article-title":"Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo Endoscopic Subscore in patients with ulcerative colitis","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0530","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/00365521.2014.883427","article-title":"The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment","volume":"49","author":"Theede","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0535","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis","volume":"6","author":"De Vos","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0540","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1007\/s10620-017-4770-0","article-title":"Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease","volume":"62","author":"Puolanne","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2018.10.010_bib0545","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","article-title":"Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn's disease","volume":"22","author":"Zittan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0550","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.gie.2017.09.011","article-title":"Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse","volume":"86","author":"Aggarwal","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.medcli.2018.10.010_bib0555","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1515\/CCLM.1999.049","article-title":"Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process","volume":"37","author":"Baveye","year":"1999","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.medcli.2018.10.010_bib0560","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.MIB.0000438428.30800.a6","article-title":"Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation","volume":"20","author":"Mooiweer","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0565","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjx088","article-title":"Accuracy of faecal immunochemical test to predict endoscopic and histological healing in ulcerative colitis: A prospective study based on validated histological scores","volume":"11","author":"Shi","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0570","first-page":"79","article-title":"Surrogate fecal biomarkers in inflammatory bowel disease: Rivals or complementary tools of fecal calprotectin?","volume":"24","author":"Di Ruscio","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0575","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11938-017-0129-z","article-title":"Utility of biomarkers in the management of inflammatory bowel disease","volume":"15","author":"Kochhar","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0580","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/ibd\/izy046","article-title":"Circulating and fecal microRNAs as biomarkers for inflammatory bowel diseases","volume":"24","author":"Sch\u00f6nauen","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0585","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/jgh.12193","article-title":"Proteomics and metabolomics in inflammatory bowel disease","volume":"28","author":"Yau","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0590","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1097\/MIB.0000000000000903","article-title":"New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes","volume":"22","author":"Barnes","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.medcli.2018.10.010_bib0595","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818769076","article-title":"Emerging concepts in non-invasive monitoring of Crohn's disease","volume":"11","author":"Marlicz","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.medcli.2018.10.010_bib0600","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: A pilot study","volume":"40","author":"Patel","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318306365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318306365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T23:47:31Z","timestamp":1662508051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775318306365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0025775318306365"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2018.10.010","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marcadores de actividad en la enfermedad inflamatoria intestinal","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2018.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}